Central and peripheral molecular targets for antiobesity pharmacotherapy

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 652-662

  Valentino, M A ^a   Lin, J E ^a   Waldman, S A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; ALS L 1023; AMFEBUTAMONE; AMINOREX; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BMS 830216; CONJUGATED LINOLEIC ACID; DEXFENFLURAMINE; DIGITALIS; DIURETIC AGENT; EPHEDRA EXTRACT; FENFLURAMINE; FUMAGILLOL CHLOROACETYLCARBAMATE; GI 181771 X; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; GREEN TEA EXTRACT; GUAR GUM; HUMAN GROWTH HORMONE[176-191][176 TYROSINE]; HYDROXYCITRIC ACID; ISPAGULA; L 796568; LAXATIVE; LY 377604; MANNAN; MK 0557; NALTREXONE; NN 9924; NOX B 11; PHENTERMINE; PHENYLPROPANOLAMINE; PYY 336; QNEXA; RAINBOW PILL; RIMONABANT; S 2367; SCH 497079; SIBUTRAMINE; SRT 2104; SRT 2379; SRT 501; TETRAHYDROLIPSTATIN; THYROID HORMONE; TKS 1225; TM 30339; TOPIRAMATE; TTT 435; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGRANULOCYTOSIS; APPETITE; BLOOD PRESSURE REGULATION; BODY WEIGHT; BRAIN HEMORRHAGE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONGENITAL MALFORMATION; DEPRESSION; DERMATITIS; DIET SUPPLEMENTATION; DISEASE CONTROL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENERGY BALANCE; EPHEDRA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPERTHERMIA; LEAN BODY WEIGHT; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW CALORY DIET; METABOLIC ACIDOSIS; MORBID OBESITY; MORBIDITY; MYOCARDIAL DISEASE; MYOPIA; NERVOUSNESS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; SUDDEN DEATH; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; OBESITY; WEIGHT LOSS;

EID: 77952584236     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.57     Document Type: Review

References (51)

1. Rodgers, A., Vaughan, P., Prentice, T., Edejer, T.T.-T., Evans, D. & Lowe, J. Reducing Risks, Promoting Healthy Life 1-248 (World Health Organization, Geneva, Switzerland, 2002).
2. Bhasin, S., Wallace, W., Lawrence, J.B. & Lesch, M. Sudden death associated with thyroid hormone abuse. Am. J. Med. 71, 887-890 (1981).
3. Dinitrophenol not acceptable for N.N.R. JAMA 105, 31-33 (1935).
4. Asher, W.L. Mortality rate in patients receiving "diet pills". Curr. Ther. Res. Clin. Exp. 14, 525-539 (1972).
5. Gurtner, H.P. Aminorex and pulmonary hypertension. A review. Cor Vasa 27, 160-171 (1985).
6. Connolly, H.M. et al. Valvular heart disease associated with fenfuramine-phentermine. N. Engl. J. Med. 337, 581-588 (1997).
7. Kernan, W.N. et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N. Engl. J. Med. 343, 1826-1832 (2000).
8. Haller, C.A. & Benowitz, N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N. Engl. J. Med. 343, 1833-1838 (2000).
9. Saper, R.B., Eisenberg, D.M. & Phillips, R.S. Common dietary supplements for weight loss. Am. Fam. Physician 70, 1731-1738 (2004).
10. Heal, D.J., Gosden, J. & Smith, S.L. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br. J. Clin. Pharmacol. 68, 861-874 (2009).
11. Erondu, N. et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 4, 275-282 (2006).
12. Sargent, B.J. & Moore, N.A. New central targets for the treatment of obesity. Br. J. Clin. Pharmacol. 68, 852-860 (2009)
13. 7TM Pharma research pipeline http://www.7tm.com/Pipeline.aspx.
14. TransTech Pharma obesity product pipeline http://www.ttpharma.com/ TherapeuticAreas/MetabolicDiseases/Obesity/TTP435/tabid/126/Default.aspx.
15. Bristol-Myers Squibb metabolics clinical trial registry http://ctr.bms.com/OneBmsCtd/InitTrialAction.do?linkname=Metabolics&type= pharma&sortby =default.
16. Ozcan, L. et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 9, 35-51 (2009).
17. Roth, J.D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. USA 105, 7257-7262 (2008).
18. 7 June 2009 Amylin Pharmaceuticals, Inc. and Eli Lilly and Company: Exenatide once weekly provided sustained improvements in glycemic control with weight loss over two years: DURATION-1 interim long-term data presented at ADA 2009 http://www.amylin.com/assets/001/5097.pdf (7 June 2009).
19. Amylin Pharmaceuticals, Inc. research pipeline http://www.amylin.com/ research/pipeline/exenatide-once-weekly.htm.
20. Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue (13 Jan 2010) http://www.novonordisk.com/press/news/news.asp?sNewsTypeGUID= &lMonth=&lYear=&sLanguageCode=&sSearchText=NN9924&sShowNews ItemGUID=acc555cc-2124-4ebf-ad6d-7f923e2e2a78&sShowLanguageCode =en-GB (13 January 2010).
21. Dakin, C.L. et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145, 2687-2695 (2004).
22. Wynne, K. et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond). 30, 1729-1736 (2006)
23. Wyeth Pharmaceuticals acquires Thiakis Limited http://www.drugs. com/news/wyeth-pharmaceuticals-acquires-thiakis-limited-15289.html (18 December 2008).
24. Larhammar, D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 65, 165-174 (1996).
25. Degen, L. et al. Efect of peptide YY3-36 on food intake in humans. Gastroenterology 129, 1430-1436 (2005).
26. Gantz, I. et al. Efcacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J. Clin. Endocrinol. Metab. 92, 1754-1757 (2007).
27. Batterham, R.L. et al. Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab. 88, 3989-3992 (2003).
28. Young, A.A. et al. Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin. Drug Dev. Res. 37, 231-248 (1996).
29. Maggs, D., Shen, L., Strobel, S., Brown, D., Kolterman, O. & Weyer, C. Efect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metab. Clin. Exp. 52, 1638-1642 (2003).
30. Date, Y. et al. The role of the gastric aferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123, 1120-1128 (2002).
31. Zorrilla, E.P. et al. Vaccination against weight gain. Proc. Natl. Acad. Sci. USA 103, 13226-13231 (2006).
32. Moran, T.H. & Dailey, M.J. Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology 150, 2526-2530 (2009).
33. Yang, J., Zhao, T.J., Goldstein, J.L. & Brown, M.S. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc. Natl. Acad. Sci. USA 105, 10750-10755 (2008).
34. Zarrindast, M.R. & Hosseini-Nia, T. Anorectic and behavioural efects of bupropion. Gen. Pharmacol. 19, 201-204 (1988).
35. Billes, S.K. & Cowley, M.A. Inhibition of dopamine and norepinephrine reuptake produces additive efects on energy balance in lean and obese mice. Neuropsychopharmacology 32, 822-834 (2007).
36. Hancock, A.A. et al. Antiobesity efects of A-331440, a novel non-imidazole histamine H 3 receptor antagonist. Eur. J. Pharmacol. 487, 183-197 (2004).
37. Gemkow, M.J., Davenport, A.J., Harich, S., Ellenbroek, B.A., Cesura, A. & Hallett, D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today 14, 509-515 (2009).
38. Obecure Phase II trial shows positive results for Histalean™ in obese women under 50 http://www.obecure.com/astatic%20news/51584.php (30 August 2007).
39. Dunk, C., Enunwa, M., De La Motte, S. & Palmer, R. Increased faecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962. Int. J. Obes. Relat. Metab. Disord. 26, (Suppl 1), S135 (2002).
40. Scacchi, M., Pincelli, A.I. & Cavagnini, F. Growth hormone in obesity. Int. J. Obes. Relat. Metab. Disord. 23, 260-271 (1999).
41. Shadid, S. & Jensen, M.D. Efects of growth hormone administration in human obesity. Obes. Res. 11, 170-175 (2003).
42. Bray, G.A. & Greenway, F.L. Pharmacological treatment of the overweight patient. Pharmacol. Rev. 59, 151-184 (2007).
43. The Phase 2B trial results for Metabolic's drug, AOD9604, do not support the commercial viability of the drug as a treatment for obesity. Development of the drug for this condition is terminated. Press release, Metabolic Pharmaceuticals, 11 February 2007
44. Phosphagenics Limited signs agreement with Metabolic Pharmaceuticals Limited http://www.phosphagenics.com/site/DefaultSite/flesystem/documents/ 20090813%20Metabolic%20Agreement.pdf (13 August 2009).
45. Eli Lilly. A weight loss study in overweight men and women http://clinicaltrials.gov/ct2/show/NCT00993421.
46. Silha, J.V., Krsek, M., Sucharda, P. & Murphy, L.J. Angiogenic factors are elevated in overweight and obese individuals. Int. J. Obes. (Lond). 29, 1308-1314 (2005).
47. Rupnick, M.A. et al. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA 99, 10730-10735 (2002)
48. AngioLab's candidates http://angiolab.co.kr
49. Sirtris pipeline http://www.sirtrispharma.com/pipeline.html.
50. Greenway, F.L. et al. Rational design of a combination medication for the treatment of obesity. Obesity 17, 30-39 (2009).
51. US Food and Drug Administration. Guidance for Industry: Developing Products for Weight Management http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf (February 2007).